FOSTER CITY, Calif., Oct. 8, 2024 /PRNewswire/ -- MicuRx Pharmaceuticals is excited to announce the publication of groundbreaking research on MRX-5, a novel oral oxaborole prodrug, demonstrating ...

Mycobacterium abscessus, a nontuberculous mycobacterium, is a significant cause of chronic pulmonary infections, particularly in individuals with compromised immune systems or structural lung ...

New treatment options for treating Mycobaterium abscessus infections are needed. Previous findings had identified the leucyl-tRNA synthetase inhibitor MRX-6038 to have significant activity against M.

Three patients developed difficult-to-treat Mycobacterium abscessus infections after receiving embryonic stem cell injections in Mexico in 2022, researchers reported. Two men -- one from Colorado and ...

Scientists at St. Jude Children's Research Hospital are tackling Mycobacterium abscessus (Mab) antibiotic resistance. This naturally antibiotic-resistant pathogen is becoming more prevalent, ...

A new PET imaging technique can accurately detect and monitor Mycobacteroides abscessus lung infections—one of the most difficult-to-diagnose conditions in patients with lung diseases. Subscribe to ...

Researchers Véronique Dartois, Ph.D., and Thomas Dick, Ph.D., of the Hackensack Meridian Center for Discovery and Innovation in Nutley, N.J. The pair work with laboratory samples in developing their ...

Epetraborole’s potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% AN2 Therapeutics, Inc. (Nasdaq: ANTX) ...

Mycobacterium abscessus is a fast-growing, pathogenic mycobacteria that can cause lung infections, and people who have respiratory conditions or are immunocompromised face a higher risk. It can also ...

Epetraborole’s potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% ...